Mounjaro Alternatives (2026): T2D-Approved GLP-1s, Tirzepatide Cousins (Zepbound), and Off-Label vs On-Label Decisions

Mounjaro is tirzepatide, FDA-approved for type 2 diabetes only — glycemic control as an adjunct to diet and exercise. The right “Mounjaro alternative” depends on what problem you're actually solving. If you want the same molecule with an easier insurance path, that's Zepbound (same tirzepatide, different FDA-approved indication). If you want a different T2D GLP-1, that's Ozempic, Trulicity, Rybelsus, or Victoza. If you were on Mounjaro off-label for weight loss, the FDA-approved weight-management options are Wegovy, Zepbound, Foundayo, and Saxenda. This article walks each path with verbatim FDA-label framing.

Mounjaro is tirzepatide — what's actually in the brand

Before we discuss alternatives, the brand-vs-molecule distinction is essential because it determines which alternatives map to which goal.

• Brand: Mounjaro (Eli Lilly).
• Active ingredient: tirzepatide — a synthetic 39-amino-acid peptide.
• Mechanism (verbatim §12.1 DailyMed): “Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.” Mounjaro is the first FDA-approved dual GIP / GLP-1 receptor agonist.
• FDA-approved indication (§1 DailyMed): adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The label may also reflect cardiovascular-risk-reduction language adopted in the 2025 label revision — verify the live DailyMed page (SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0) for current verbatim wording before quoting.
• FDA-approval date: May 13, 2022.
• Dose range: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg once weekly subcutaneous injection. Mounjaro and Zepbound share the same dose ladder.

Mounjaro is NOT FDA-approved for weight loss. Off-label prescribing for weight loss is legal and clinically common, but it is rarely insurance-covered for non-T2D patients because both Cigna CNF 360 and Aetna 2439-C explicitly gate Mounjaro behind a documented type 2 diabetes diagnosis. For the deep-dive on the T2D-only label and how it differs from Zepbound's weight-management label, see Mounjaro vs Zepbound FDA prescribing information explained.

Why are you looking for a Mounjaro alternative?

Three distinct goals show up under the same search query. Pick yours and skip to that section:

• Goal A — same tirzepatide molecule, different indication / cheaper insurance path. Switch to Zepbound. Same active ingredient. Different FDA-approved indication (chronic weight management + obstructive sleep apnea). Often a different formulary tier and a separate self-pay path through LillyDirect.
• Goal B — different T2D-indicated GLP-1. Mounjaro intolerance, supply, formulary, or cost is driving you off tirzepatide and you still need a T2D drug. Options: Ozempic (semaglutide), Trulicity (dulaglutide), Rybelsus (oral semaglutide), Victoza (liraglutide).
• Goal C — you were on Mounjaro off-label for weight loss. The on-label path is to switch to an FDA-approved weight-management drug: Wegovy, Zepbound, Foundayo, or Saxenda. Insurance coverage gets easier (weight-management formulary instead of T2D formulary).

Goal A — Same molecule, different label: Zepbound

Zepbound is tirzepatide — the same active ingredient as Mounjaro, manufactured by the same company (Eli Lilly), in the same dose range (2.5 mg through 15 mg once weekly), with the same §12.1 mechanism-of-action language. The differences are entirely on the label, the indication, and the formulary side.

When Zepbound is the right Mounjaro alternative:

• You started Mounjaro off-label for weight loss without a T2D diagnosis and your insurance denied coverage. Switching to Zepbound aligns the prescription with an FDA-approved indication that BMI-eligible patients can often get covered.
• You have T2D plus obesity and your formulary covers Zepbound on the weight-management tier but charges a higher copay for Mounjaro. Your prescriber can write Zepbound for the obesity indication while continuing T2D management with metformin and other agents.
• You're paying cash. LillyDirect Self Pay vials of Zepbound at $299–$449/month are dramatically cheaper than retail Mounjaro pens.

When Zepbound is NOT the right swap: if your primary clinical need is glycemic control for T2D and your insurance covers Mounjaro on the diabetes formulary, there is no clinical reason to switch — Zepbound is not labeled for T2D, and a Zepbound prescription would not have the same pharmacy-benefit pathway for diabetes management. For more on the indication switch mechanics see Wegovy ↔ Zepbound switch & dose equivalence guide (the same logic applies to Mounjaro ↔ Zepbound — same molecule, no dose conversion needed).

Goal B — Different T2D-indicated GLP-1s (Ozempic, Trulicity, Rybelsus, Victoza)

If you want to stay on a GLP-1 class drug FDA-approved for type 2 diabetes but switch off tirzepatide — typically because of GI tolerance, supply, formulary, or cost — these are the FDA-approved options as of May 2026:

All four are FDA-approved for type 2 diabetes mellitus glycemic control as an adjunct to diet and exercise. Cardiovascular and kidney secondary indications differ — see the verbatim §1 sections of each DailyMed label for the precise language. Ozempic and Rybelsus are the same active ingredient (semaglutide) in different formulations; Trulicity is a different molecule (dulaglutide); Victoza is a different molecule (liraglutide).

Trulicity is a BLA biologic — generic-pathway distinction. Trulicity (dulaglutide) is an Fc-fusion biologic licensed under a Biologics License Application (BLA), not an NDA. This is operationally relevant because biologics go off-patent through the biosimilar pathway, not the small-molecule-generic pathway. Ozempic, Mounjaro, and Wegovy are NDA peptides and will eventually face generic peptide competition; Trulicity will face biosimilars instead. For the full timeline see our GLP-1 generic timeline article.

SURPASS-2: tirzepatide is more effective than semaglutide for T2D — but that doesn't make Ozempic worse for every patient

SURPASS-2 (Frías et al., NEJM 2021, PMID 34170647) is the direct head-to-head trial of tirzepatide (Mounjaro) vs semaglutide 1 mg (Ozempic) in adults with type 2 diabetes inadequately controlled on metformin. The trial randomized 1,879 patients to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or semaglutide 1 mg weekly, for 40 weeks.

• HbA1c reduction at 40 weeks: tirzepatide 5 mg = −2.01%, 10 mg = −2.24%, 15 mg = −2.30%; semaglutide 1 mg = −1.86%. All three tirzepatide doses produced statistically superior HbA1c reduction.
• Body weight reduction: tirzepatide 5 mg = −7.6 kg, 10 mg = −9.3 kg, 15 mg = −11.2 kg; semaglutide 1 mg = −5.7 kg. Tirzepatide produced greater weight loss at every dose.
• Adverse events: nausea, diarrhea, and vomiting were the most common adverse events for both drugs, with similar overall frequency.

SURPASS-2 establishes that tirzepatide is superior to semaglutide 1 mg on the two primary outcomes that matter for T2D management. That said, Ozempic now goes up to 2 mg weekly (not the 1 mg dose tested in SURPASS-2), and the FLOW trial (2024) added a kidney-disease secondary indication to the Ozempic label that Mounjaro does not have. The practical implication is that tirzepatide produces larger glycemic and weight effects, but Ozempic may still be the right drug for a T2D patient with chronic kidney disease, for a patient who tolerated the GI side-effect profile of semaglutide but not tirzepatide, or for a patient whose formulary covers Ozempic at lower copay than Mounjaro.

The deeper SURPASS-2 walk-through and the related dose-vs-dose comparison is in our Mounjaro vs Ozempic for diabetes (SURPASS-2) deep-dive.

Cross-class T2D options that are NOT GLP-1s

If GLP-1 / GIP class side effects (nausea, vomiting, GI upset, gallbladder events) are the reason you're leaving Mounjaro, the cross-class T2D options are worth a structured discussion with your endocrinologist. None produces the weight-loss magnitude of tirzepatide, but they have different side-effect profiles and cardiovascular / kidney evidence bases.

• Metformin (biguanide). First-line per the ADA Standards of Care. Generic. Cheap. GI side effects (~25%) generally resolve with extended-release formulation and titration. No clinically meaningful weight loss; weight neutral. The starting point of nearly every T2D regimen.
• SGLT2 inhibitors — Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin), Steglatro (ertugliflozin). Once-daily oral. Glycemic control plus cardiovascular and kidney benefits established in EMPA-REG OUTCOME, DECLARE-TIMI 58, DAPA-CKD, EMPA-KIDNEY, and CREDENCE. Modest weight loss (~2–3 kg). Volume depletion and genital mycotic infection risks. Heart-failure indications (with or without diabetes) for several agents.
• DPP-4 inhibitors — Januvia (sitagliptin), Tradjenta (linagliptin), Onglyza (saxagliptin). Once-daily oral. Weight neutral. Generally well tolerated; risk of pancreatitis and joint pain. No cardiovascular outcome benefit (CV-neutral in trials).
• Insulin (basal, prandial, premixed). The definitive glycemic-control tool when oral and GLP-1 agents are insufficient. Weight gain is common. Hypoglycemia risk. Modern basal analogs (glargine U-300, degludec) reduce hypoglycemia compared with NPH.
• Sulfonylureas, TZDs, alpha-glucosidase inhibitors. Older classes. Sulfonylureas (glimepiride, glipizide) cause hypoglycemia and weight gain. Pioglitazone (TZD) causes weight gain and fluid retention but has independent cardiovascular evidence (PROactive). Acarbose is rarely used in the US.

For the broader T2D-vs-weight-loss disambiguation — which drugs are FDA-approved for which condition and why insurance treats them differently — see Diabetes vs weight loss GLP-1 medication disambiguation.

Goal C — If you were on Mounjaro for weight loss off-label

A large share of Mounjaro prescriptions in 2022–2024 were written off-label for weight loss in patients without T2D. That practice is legal — clinicians can prescribe an FDA-approved drug off-label — but it is increasingly difficult to insurance-cover, because formulary committees explicitly require an ICD-10 E11.x diagnosis for Mounjaro coverage. The on-label alternative for the weight-loss goal is a drug FDA-approved for chronic weight management.

The first-pass on-label substitute for Mounjaro off-label use is Zepbound. Same tirzepatide molecule. Same dose ladder. The only thing that changes is the indication on the label and the formulary tier the insurer applies. For T2D patients who lost their Mounjaro coverage but qualify for weight-management coverage, Zepbound preserves the molecule and the dose; for non-T2D patients who were paying cash for Mounjaro, Zepbound vials through LillyDirect are dramatically cheaper than retail Mounjaro.

For the head-to-head Wegovy vs Mounjaro comparison — different molecules, different mechanisms, different trial populations — see Wegovy vs Mounjaro decision guide. For the brand-name disambiguation, see Wegovy / Ozempic / Zepbound / Mounjaro brand-name cheat sheet.

Foundayo: oral alternative for the off-label-weight-loss patient

If your reason for leaving Mounjaro is needle aversion or injection logistics, Foundayo (orforglipron) is the FDA-approved oral alternative for chronic weight management. Foundayo was approved April 1, 2026, and is the first FDA-approved non-peptide small-molecule GLP-1 receptor agonist — important because non-peptide structure means no fasting restriction (unlike Rybelsus, which requires fasted dosing with no more than 4 ounces of water).

• Verbatim §1 indication (DailyMed SetID 8ac446c5-feba-474f-a103-23facb9b5c62): Foundayo is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with obesity or with overweight in the presence of at least one weight-related comorbid condition.
• Route + frequency: Once daily oral tablet. No fasting required.
• Self-pay path: $149/month at LillyDirect Self Pay Pharmacy and Amazon Pharmacy (verified 2026-05-09).
• Trade-off vs tirzepatide: trial weight loss in the ~12–15% range based on late-phase data; tirzepatide's SURMOUNT-1 result was ~20.9% at 15 mg for 72 weeks. Foundayo is the most accessible and the cheapest FDA-approved weight-management drug, but is not the most efficacious head-to-head.

For the deeper Foundayo evidence walk-through see Foundayo (orforglipron) FDA approval & evidence and Foundayo vs Wegovy vs Zepbound comparison. For the dose-equivalence math when switching from a tirzepatide injection to oral orforglipron see Foundayo ↔ Zepbound switch & dose equivalence guide.

Cost considerations

Verified live on 2026-05-09 from manufacturer self-pay portals (NovoCare, LillyDirect) and retailer programs (Costco Member Prescription Program via Sesame, Sam's Club Plus Pharmacy, Amazon Pharmacy):

• Mounjaro cash retail: ~$1,000+/month for the standard pen at most US retail pharmacies. Manufacturer commercial-insurance copay savings card brings eligible commercially insured patients to $25/month for covered prescriptions.
• Zepbound LillyDirect Self Pay vials: $299 (2.5 mg starter), $349 (5 mg), $499 (7.5 mg), $599 (10 mg) per month. Single-dose vials, patient self-draws with provided syringe.
• Wegovy NovoCare Pharmacy: $299/month standard pen self-pay (verified 2026-05-09 — the older $499 figure is outdated). $399/month for the Wegovy HD 7.2 mg pen. $149/month for the Wegovy oral pill (1.5 mg / 4 mg) through August 31, 2026.
• Ozempic NovoCare: $199/month new-patient for first two months, then $349/month standard.
• Costco Member Prescription Program (CMPP) via Sesame: Wegovy + Ozempic at $349/month; new-patient pricing $199/month for the first two months. Membership-gated for the discount.
• Sam's Club Plus Pharmacy: oral Wegovy 1.5 mg at $149/month (launched January 2026); pen formulations of Wegovy + Ozempic at $499/month via the Novo Nordisk Copay Savings Program.
• Foundayo: $149/month at LillyDirect Self Pay Pharmacy or Amazon Pharmacy.

For the channel-by-channel cash-pay walkthrough see Wegovy GoodRx + cash-pay coupon & channel guide. For the 12-month price-movement analysis on the compounded side see compounded GLP-1 price movement (12 months).

Insurance / formulary considerations: T2D vs weight-management coverage

Insurance plans treat T2D and chronic weight management as two separate formulary categories — and most plans cover them under different prior-authorization criteria.

• T2D formulary (Mounjaro, Ozempic, Trulicity, Rybelsus, Victoza): nearly all commercial plans cover this category. Prior auth typically requires a documented T2D diagnosis (ICD-10 E11.x) and, in many cases, step therapy through metformin first. Cigna CNF 360 and Aetna 2439-C are the canonical commercial PA criteria.
• Weight-management formulary (Wegovy, Zepbound, Foundayo, Saxenda, Qsymia, Contrave, Xenical): coverage is plan-specific. Many commercial plans exclude anti-obesity drugs entirely. When covered, prior auth typically requires BMI ≥30 (or ≥27 with weight-related comorbidity), documentation of prior diet/exercise attempts, and sometimes participation in a structured weight-management program. Medicare Part D historically excluded anti-obesity drugs by statute (the Medicare Modernization Act of 2003 specifically excluded weight-loss drugs); the 2025 cardiovascular indication on Wegovy (SELECT trial) opened a partial Medicare pathway for patients with established cardiovascular disease.

Practical implication: if you're losing Mounjaro coverage because your insurer doesn't see a T2D diagnosis on your chart, the on-label fix is to switch to Zepbound (or Wegovy/Foundayo/Saxenda) and submit a weight-management PA. If you're losing Mounjaro coverage because your plan excludes weight-management drugs entirely, Zepbound won't fix that — you would need either an appeal, an HSA/FSA cash-pay path, or to pursue T2D documentation if clinically appropriate. For the appeal-letter mechanics see GLP-1 insurance dropped coverage appeal playbook. For the Medicare/Medicaid coverage map see GLP-1 insurance coverage: Medicare, Medicaid, commercial.

Bottom line

• Same molecule, weight-management label: Zepbound. The default Mounjaro alternative for non-T2D patients losing coverage and for T2D + obesity patients whose plan covers weight-management drugs separately.
• Different T2D-indicated GLP-1: Ozempic (semaglutide injection), Trulicity (dulaglutide injection), Rybelsus (oral semaglutide), Victoza (liraglutide injection). All FDA-approved for T2D glycemic control; differ in cardiovascular and kidney secondary indications.
• Off-label weight-loss patient → on-label weight-management drug: Wegovy, Zepbound, Foundayo, or Saxenda. Wegovy NovoCare $299/mo and Foundayo $149/mo are the cheapest verified brand-name self-pay paths in the class.
• Tirzepatide is the single most efficacious GLP-1 class drug in head-to-head data (SURPASS-2 for T2D, SURMOUNT-5 for weight loss) — but a less efficacious drug a patient actually tolerates and stays on long-term beats a more efficacious drug they discontinue. Switching is always a clinical decision, not just an arithmetic one.
• Verify pricing live. Cash-pay programs re-price frequently. Every figure in this article was verified on 2026-05-09 — re-check NovoCare, LillyDirect, and the Sam's Club / Costco / Amazon Pharmacy pages before you switch.

Related research

• Mounjaro vs Zepbound FDA prescribing information explained — verbatim §1 indication, §2 dosing, §4 contraindications, §5 boxed warning for both labels.
• Mounjaro vs Zepbound complete comparison — same-molecule comparison with the indication and formulary differences.
• Mounjaro vs Ozempic for diabetes (SURPASS-2) — verbatim head-to-head trial walk-through.
• Wegovy vs Mounjaro decision guide — different-molecule weight-loss vs T2D framing.
• Diabetes vs weight loss GLP-1 medication disambiguation — which GLP-1s are FDA-approved for which condition.
• Ozempic alternatives complete guide — semaglutide-anchored sister article.
• Foundayo vs Wegovy vs Zepbound comparison — oral vs injectable weight-management decision.
• GLP-1 generic timeline — when tirzepatide, semaglutide, dulaglutide, and liraglutide go off-patent (NDA generic vs BLA biosimilar pathway).